Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy

Peer Review reports

Original Submission
26 Jul 2018	Submitted	Original manuscript
5 Nov 2018	Reviewed	Reviewer Report - John Varlotto
27 Dec 2018	Reviewed	Reviewer Report - Reviewer 2
20 Jan 2019	Author responded	Author comments - Milana Bergamino
Resubmission - Version 2
20 Jan 2019	Submitted	Manuscript version 2
8 Feb 2019	Reviewed	Reviewer Report - John Varlotto
Resubmission - Version 3
	Submitted	Manuscript version 3
Publishing
11 Feb 2019	Editorially accepted
21 Feb 2019	Article published	10.1186/s12885-019-5370-5

Back to article page